Acquired Companies
Since its inception, Sanderling has supported more than 90 new start-up biomedical companies, and has consistently earned high rates of return, building a superior track record of success. Selected examples of acquired companies are listed below:
 |
Actimis Pharmaceuticals, focused on the development of small molecule therapeutics for respiratory and inflammatory disorders including atopic dermatitis and asthma. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. |
Actimis Pharmaceuticals, Inc. Acquired by Boehringer Ingelheim www.boehringer-ingelheim.com |
|
Advanced Cardiovascular Systems was a pioneer in the manufacture of percutaneous angioplastic "balloon" catheters. The company was founded in 1981 and aquired by Eli Lilly in 1984 for stock on an earn-out basis. The Company became a leader in its field, commercializing catheters for angioplasty. It was spun off as part of Guidant in 1994. |
Advanced Cardiovascular Systems Acquired by Guidant Corp. (now Boston Scientific) NYSE: BSX www.bostonscientific.com |
|
Aderis Pharmaceuticals, formerly Discovery Therapeutics, developed novel small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases. |
Aderis Pharmaceuticals, Inc. Acquired by Schwarz Pharma www.ucb.com |
 |
BioSpace, Inc. provides web-based information services that enable life science companies to more efficiently access, deliver and share information. The company's Website, www.biospace.com remains the Internet's most comprehensive life sciences-related information resource. | BioSpace, Inc. |
 |
Gemin X Biotechnologies Inc. seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis. Gemin X's research focus on the Bcl-2 and p53 pathways has led to the discovery of novel small molecules that selectively restore the cell death program in cancer cells. | Gemin X Biotechnologies, Inc. Acquired by Cephalon, Inc. NASDAQ: CEPH www.cephalon.com |
 |
Kadmus developed novel products for a variety of conditions through the inhibition of endocannabinoid degradation (FAAH inhibitors), activation of endocannabinoid related pathways (OEA), and activation of peripheral cannabinoid receptors. |
Kadmus Pharmaceuticals, Inc. Acquired by Schering Plough www.merck.com |
 |
Stentor was acquired by Philips in 2005, having developed an enterprise-wide imaging and information solution for the healthcare industry. Its technology was the first viable option for the dynamic real time transfer of high quality images across the healthcare enterprise using existing networks and standard PC's. |
Stentor, Inc. Acquired by Philips NYSE: PHG www.philips.com |
 |
Taligen Therapeutics is focused on developing innovative technologies to manipulate complement proteins of the immune system to inhibit inflammation and to target inhibitors of inflammation to specific sites of tissue injury. | Taligen Therapeutics, Inc. Acquired by Alexion Pharmaceuticals, Inc. NASDAQ: ALXN www.alxn.com |
 |
UltraBridge is a technology solution provider to the long term care industry. Built upon a deep knowledge and understanding of the industry operations, UltraBridge provides its clients with a comprehensive management solution to their data and business reporting needs using outsourcing. |
UltraBridge, Inc. Acquired by CareCentric www.carecentric.com |
 |
Acquired by St. Jude Medical, Ventritex was a leader in the field of implantable defibrillators. Their device was designed to monitor the heart, determine if the heart is undergoing fibrillation, defibrillate the heart, record an EKG and report data on demand to the physician. |
Ventritex Acquired by ST. JUDE MEDICAL NYSE: STJ www.sjm.com |